INTRODUCTION
Acinetobacter baumannii is an omnipresent nonfermentative gram negative microorganism that frequently colonizes in the skin and upper respiratory tract of hospitalized patients. [1, 2] In two recent decades multiple antibioticresistant strains of this microorganism have been implicated in nosocomial infections occurring in intensive care units (ICUs) worldwide. [3] [4] [5] Acinetobacter spp may lead to various types of infections include pneumonia, urinary tract infection, endocarditis, surgical site infection, meningitis, military injuries, and septicemia. [1, 3, 6] A. baumannii clinical isolates has increased worldwide especially in some Asian countries and it is classifi ed as a diffi cult nosocomial infection to treat and control. [7, 8] In the United States and Europe, A. baumannii accounts for 2.5-10% of all infections caused by gram negative bacteria seen in ICUs. [9, 10] There is li le information about antibiotic resistance of Acinetobacter spp in hospitals of Iran. Reported A. baumannii prevalence in only two studies on ICU patients in our country was 3.75 and 22.4%, respectively. [11, 12] It is increasingly recognized as an important cause of community-acquired pneumonia, with a high mortality rate of 40-64%. [10, [13] [14] [15] Multidrug resistant prevalence of Acinetobacter spp. has been rising and the choice of treatment with usually
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MATERIALS AND METHODS
Bacterial isolates
This is a cross-sectional study carried out in medical and surgical ICUs of Alzahra Hospital, Isfahan, Iran. The study was performed on 70 strains of A. baumannii isolates from diff erent patients of fi ve ICUs between March 2011 and June 2012. All expected Acinetobacter isolates, which were nonhemolytic, oxidase-negative, non-lactose fermentative, and gram-negative diplococci, were identifi ed as A. baumannii by using the conventional biochemical tests and growth potential at 37 and 44°C. [22] Antimicrobial susceptibility testing Antimicrobial susceptibility tests was carried out on all isolates of A. baumannii using the Kirby-Bauer Disk Diff usion Agar method according to Clinical Laboratory Standard Institute (CLSI) guidelines for 10 antibiotics [ Table 1 ]. Susceptibility against ciprofl oxacin and levofl oxacin were established by epsilometer (E-test) method recommended by CLSI (Liofi lchem, Italy). The breakpoints proposed by CLSI were used for ciprofl oxacin (susceptible 1 mg/mL; resistant 4 mg/mL) and levofl oxacin (susceptible 2 mg/ mL; resistant 8 mg/mL). The interpretive criteria used were those established in CLSI standard Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as control strains. [23] Polymerase chain reaction (PCR) amplification and restriction fragment length polymorphism O l i g o n u c l e o t i d e p r i m e r s , 5 ' -A A A C C T G T T C A G C G C C G C A T T -3 ' a n d 5'-AAAGTTGTCTTGCCATTCACT-3' were used for Ser80 mutation within parC. Bacterial DNA PCR isolated as previously described. [1] The PCR product was digested with HinfI under conditions recommended by the manufacturer. [1] Both strands of amplifi ed DNA specimens that had not shown this mutation were sequenced using forward parC primer. DNA sequences obtained were initially aligned with known sequences by using the BLASTX option (at the National Center for Biotechnology Information (NCBI) website) to generate amino acid alignment within the quinolone resistance determining regions (QRDRs). Sequence comparisons were made to the wild-type A. baumannii parC (GenBank accession no. X95819) QRDRs. [10] 
RESULTS
Seventy isolates of A. baumannii from ICUs were studied (respiratory specimens, n = 23; urine samples, n = 16; blood specimens, n = 11; tracheal aspirates specimens, n = 5; cerebrospinal fluid (CSF) specimens, n = 5; and injuries specimens n = 10). Antimicrobial resistance rates of diff erent antibiotics for A. baumannii isolated from the ICU of Alzahra Hospital are shown in Table 1 . In disk diff usion method gentamicin, levofl oxacin and ciprofl oxacin (100%) and meropenem and ampicillin/sulbactam (90%) resistant antimicrobial agents against A. baumannii strains. We could fi nd no relation between antibiotic therapy and mutation in parC gene (P = 0.68).
Of the 70 isolates, 68 (97.1%) were multidrug resistant. 77.1% (54/70) were resistant to imipenem, amikacin, and ampicillinsulbactam; thus classifying these isolates as highly resistant. In our study, respiratory and CSF specimens showed the highest and lowest resistance respectively [ Figure 1 ]. The minimal inhibitory concentrations (MICs) of ciprofl oxacin were still high, but MICs of levofloxacin were nearly intermediate breakpoint in 23 isolates [ Table 2 ]. Mutation of parC in A. baumannii, a fragment of the parC gene including the QRDR then parC was analyzed by PCR in 70 clinical isolates [ Figure 2 ]. A er digestion by restriction enzyme, the PCR products of parC amplifi ed from wild type strain generated two fragment of 206 and 121 bp; whereas, Ser80 to Leu mutant strain remained 327 bp. Mutation at position 80 in parC was observed in 65 (93%) isolates. Sequencing results of fi ve A. baumannii clinical isolates were similar to each other, also our results didn't reveal any changes in amino acid sequences. 
DISCUSSION
It is widely known that quinolone resistance; amino acid substitutions in gyrA and parC have important functions in gram negative bacilli. [16] The donation of amino acid substitutions in gyrA and parC to quinolone resistance may be variable among diff erent gram negative bacilli. In Pseudomonas aeruginosa, the fl uoroquinolone resistance is principally because of gyrA mutations with parC mutations being less important. [24] Three or four mutations in both gyrA and parC genes are required for high-level resistance to ciprofl oxacin in E. coli, but double mutations in gyrA and parC were needed for high level resistance to quinolones in A. baumannii. [19] Our study showed that mutation at position 80 in parC was observed in 93% of isolates in A. baumannii in Iran and all of which are resistance to ciprofl oxacin and levofl oxacin. Sequencing results of fi ve A. baumannii clinical isolates had not any changes, also no amino acid sequence changes were observed. It is probably due to mutation of gyrA alone, activated effl ux pumps or mutation of parE. In a previous similar study that was performed in Korea, no mutation of gyrA and parC was found in six out of 59 clinical isolates in A. baumannii which are sensitive to ciprofl oxacin and gatifl oxacin. Nearly 90% of these isolates are resistant to ciprofl oxacin and included at least one mutation with substitution of Leu for Ser80 in parC. [16] Similar to other reports, our results showed high incidence of mutation of parC in A. baumannii in Iran; in contrast, low frequency of mutation of gyrA and parC was detected in A. baumannii isolates of Taiwan. [1] It is well approved that mutation of gyrA and parC play a signifi cant function in drug resistance. A logical interpretation is the mutation outside Ser80 in parC region may be more important in drug resistance in Iran (mutation in 7% of our isolates probable due to mutation of gyrA alone, activated effl ux pumps or mutation of parE). In addition to mutations in DNA gyrase and topoisomerase IV effl ux pump which increases the accumulation of drug may also include in multidrug-resistant isolates.
CONCLUSION
High percentage of MDR A. baumannii isolates (97.1%) was found in our country, yet high proportion of these isolates had a mutation in parC. Also mutation of parC in our country may play an important role in increased incidence of MDR A. baumannii and rapid detection of quinolone-resistance A. baumannii isolates can help physicians to justly treat these infections. 
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